EUVIMEDEUVIMED entdecken
Open Access

Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis

Xiumeng Hua, Zhe Sun, Ziwei Liang, Yanhong Huang, Han Mo, Fei Dong, Shimin Mo, Xingyue Yang, Ningning Zhang, Xiao Chen, Shumin Liao, Zhen Qi und 5 weitere

Theranostics · 01.01.2026 · 16 (4) · 2037-2051

DOI: 10.7150/thno.116749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 01.01.2026. Verfasst von Xiumeng Hua und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and …. Hauptthemen laut MEDLINE: Myocarditis, T-Lymphocytes, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: FAP.CAR-T cells eliminate fibrosis-driving myofibroblasts, reversing cardiac dysfunction in chronic myocarditis. This strategy, validated in human organoids, offers translatable immunotherapy for fibrosis-driven heart disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisT-LymphocytesCell- and Tissue-Based TherapyHumansAnimalsFibrosisMiceOrganoidsDisease Models, AnimalMyocardiumSerine EndopeptidasesChronic DiseaseMembrane ProteinsMyofibroblastsEndopeptidasesMaleFemaleFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

CAR-Tfibroblast activation protein-αmyocardial fibrosismyocarditis

Substanzen

Serine EndopeptidasesMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
  • Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
  • Shenzhen State Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518038, China.
  • Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • 1 EvoLab, ACROBiosystems Inc, Beijing 100176, China.

Zitieren

APA

Hua, X., Sun, Z., Liang, Z., Huang, Y., Mo, H., Dong, F., Mo, S., Yang, X., Zhang, N., Chen, X., Liao, S., Qi, Z., Zhang, R., Guan, S., Li, L., Xu, Y., & Song, J. (2026). Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis. Theranostics, 16(4), 2037-2051. https://doi.org/10.7150/thno.116749

Vancouver

Hua X, Sun Z, Liang Z, Huang Y, Mo H, Dong F, et al. Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis. Theranostics. 2026;16(4):2037-2051. doi:10.7150/thno.116749

BibTeX
@article{Hua2026,
  author = {Hua, Xiumeng and Sun, Zhe and Liang, Ziwei and Huang, Yanhong and Mo, Han and Dong, Fei and Mo, Shimin and Yang, Xingyue and Zhang, Ningning and Chen, Xiao and Liao, Shumin and Qi, Zhen and Zhang, Rosanna and Guan, Shuge and Li, Liang and Xu, Yang and Song, Jiangping},
  title = {Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {2037--2051},
  doi = {10.7150/thno.116749}
}
Kostenlos starten →